These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26275900)

  • 1. Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
    Preiss D; Thomas LE; Wojdyla DM; Haffner SM; Gill JM; Yates T; Davies MJ; Holman RR; McMurray JJ; Califf RM; Kraus WE;
    BMJ Open; 2015 Aug; 5(8):e007901. PubMed ID: 26275900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
    Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
    Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
    Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.
    Yates T; Davies MJ; Haffner SM; Schulte PJ; Thomas L; Huffman KM; Bales CW; Preiss D; Califf RM; Holman RR; McMurray JJ; Bethel MA; Tuomilehto J; Kraus WE
    Diabet Med; 2015 Aug; 32(8):1090-6. PubMed ID: 25818859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
    Preiss D; Giles TD; Thomas LE; Sun JL; Haffner SM; Holman RR; Standl E; Mazzone T; Rutten GE; Tognoni G; Chiang FT; McMurray JJ; Califf RM
    Stroke; 2013 Sep; 44(9):2590-3. PubMed ID: 23899915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
    ; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
    N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
    Latini R; Staszewsky L; Sun JL; Bethel MA; Disertori M; Haffner SM; Holman RR; Chang F; Giles TD; Maggioni AP; Rutten GE; Standl E; Thomas L; Tognoni G; Califf RM; McMurray JJ
    Am Heart J; 2013 Nov; 166(5):935-40.e1. PubMed ID: 24176451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of valsartan on the incidence of diabetes and cardiovascular events.
    ; McMurray JJ; Holman RR; Haffner SM; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
    N Engl J Med; 2010 Apr; 362(16):1477-90. PubMed ID: 20228403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
    Wong YW; Thomas L; Sun JL; McMurray JJ; Krum H; Hernandez AF; Rutten GE; Leiter LA; Standl E; Haffner SM; Mazzone T; Martinez FA; Tognoni G; Giles T; Califf RM
    Circ Heart Fail; 2013 Mar; 6(2):203-10. PubMed ID: 23388113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
    Scheen AJ
    Rev Med Liege; 2010 Apr; 65(4):217-23. PubMed ID: 20499825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
    Shen L; Shah BR; Reyes EM; Thomas L; Wojdyla D; Diem P; Leiter LA; Charbonnel B; Mareev V; Horton ES; Haffner SM; Soska V; Holman R; Bethel MA; Schaper F; Sun JL; McMurray JJ; Califf RM; Krum H
    BMJ; 2013 Dec; 347():f6745. PubMed ID: 24322398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
    Chatterjee R; Thomas L; Svetkey L; Brancati FL; Califf RM; Edelman D
    Am J Hypertens; 2013 Jun; 26(6):723-6. PubMed ID: 23417031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
    Huffman KM; Sun JL; Thomas L; Bales CW; Califf RM; Yates T; Davies MJ; Holman RR; McMurray JJ; Bethel MA; Tuomilehto J; Haffner SM; Kraus WE
    Metabolism; 2014 Apr; 63(4):554-61. PubMed ID: 24559843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
    Katz M; Califf RM; Sun JL; McMurray JJ; Thomas L; Lopes RD
    Am J Med; 2015 Mar; 128(3):297-302. PubMed ID: 25447626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES; Foley JE; Shen SG; Baron MA
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial.
    Kraus WE; Yates T; Tuomilehto J; Sun JL; Thomas L; McMurray JJV; Bethel MA; Holman RR
    BMJ Open Diabetes Res Care; 2018; 6(1):e000523. PubMed ID: 30073088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.
    Preiss D; Haffner SM; Thomas LE; Sun JL; Sattar N; Yates T; J Davies M; McMurray JJ; Holman RR; Califf RM; Kraus WE
    Diabetes Obes Metab; 2014 Dec; 16(12):1265-8. PubMed ID: 24861892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial.
    Lian F; Li G; Chen X; Wang X; Piao C; Wang J; Hong Y; Ba Z; Wu S; Zhou X; Lang J; Liu Y; Zhang R; Hao J; Zhu Z; Li H; Fang Liu H; Cao A; Yan Z; An Y; Bai Y; Wang Q; Zhen Z; Yu C; Wang CZ; Yuan CS; Tong X
    J Clin Endocrinol Metab; 2014 Feb; 99(2):648-55. PubMed ID: 24432995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.